Literature DB >> 2040177

Subcutaneous erythropoietin therapy: comparison of three different sites of injection.

I C Macdougall1, J M Jones, M I Robinson, J B Miles, G A Coles, J D Williams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2040177     DOI： 10.1159/000419525

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN： 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  13 in total

Review 1.  Pharmacokinetics/pharmacodynamics of recombinant human erythropoietins in doping control.

Authors:  Emmanuelle Varlet-Marie; Aurélie Gaudard; Michel Audran; Francoise Bressolle
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

2.  Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats.

Authors:  Leonid Kagan; Jie Zhao; Donald E Mager
Journal:  Pharm Res       Date:  2014-05-23       Impact factor: 4.200

3.  Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats.

Authors:  Leonid Kagan; Michael R Turner; Sathy V Balu-Iyer; Donald E Mager
Journal:  Pharm Res       Date:  2011-09-02       Impact factor: 4.200

Review 4.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

Review 5.  Controversies in determination of epoetin (recombinant human erythropoietin) dosages.

Authors:  P A Abraham; W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

6.  Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-04-30       Impact factor: 4.009

7.  The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites.

Authors:  J D Jensen; L W Jensen; J K Madsen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 8.  Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.

Authors:  C J Dunn; A Markham
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

9.  Interspecies modeling and prediction of human exenatide pharmacokinetics.

Authors:  Ting Chen; Donald E Mager; Leonid Kagan
Journal:  Pharm Res       Date:  2012-11-15       Impact factor: 4.200

Review 10.  Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  Drugs       Date:  2004       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.